<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/" >

<channel>
	<title>MRK &#8211; Stock Earnings</title>
	<atom:link href="https://cms.stocksearning.com/tag/mrk/feed/" rel="self" type="application/rss+xml" />
	<link>https://cms.stocksearning.com</link>
	<description>Empowering Investors and Traders</description>
	<lastBuildDate>Fri, 13 Nov 2026 21:01:48 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>

<image>
	<url>https://cms.stocksearning.com/wp-content/uploads/2025/10/cropped-cropped-SE_lovo_bimi-32x32.jpg</url>
	<title>MRK &#8211; Stock Earnings</title>
	<link>https://cms.stocksearning.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>An Update on the 2026 Dogs of the Dow Strategy</title>
		<link>https://cms.stocksearning.com/2026/11/update-2026-dogs-of-the-dow-strategy-2/</link>
					<comments>https://cms.stocksearning.com/2026/11/update-2026-dogs-of-the-dow-strategy-2/#respond</comments>
		
		<dc:creator><![CDATA[Ian Cooper]]></dc:creator>
		<pubDate>Fri, 13 Nov 2026 21:00:00 +0000</pubDate>
				<category><![CDATA[Evergreen]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[HD]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[KO]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[NKE]]></category>
		<category><![CDATA[PG]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[VZ]]></category>
		<guid isPermaLink="false">https://cms.stocksearning.com/?p=10458</guid>

					<description><![CDATA[The Dogs of the Dow are proving their value in 2026, with several of this year’s top-yielding Dow components already posting impressive gains. ]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">For investors looking to build wealth with blue-chip dividend stocks, few strategies have stood the test of time like the&nbsp;<a href="https://www.dogsofthedow.com/" target="_blank" rel="noopener">Dogs of the Dow</a>.&nbsp;The simple approach focuses on buying the 10 highest-yielding stocks in the Dow Jones Industrial Average at the beginning of each year and holding them for 12 months.</p>



<div class="wp-block-rank-math-toc-block" id="rank-math-toc"><h2>Table of Contents</h2><nav><ul><li><a href="#the-dogs-of-the-dow-are-having-a-strong-year">The Dogs of the Dow Are Having a Strong Year</a></li><li><a href="#why-this-strategy-still-works">Why This Strategy Still Works</a></li><li><a href="#a-simple-strategy-for-long-term-wealth">A Simple Strategy for Long-Term Wealth</a></li></ul></nav></div>



<p class="wp-block-paragraph">Historically, the strategy has generated competitive returns, strong dividend income, and downside protection during volatile markets.&nbsp;After another solid showing in 2025, the <a href="https://www.dogsofthedow.com/2026-dogs-of-the-dow.htm" target="_blank" rel="noopener">Dogs of the Dow</a> are once again proving their value in 2026, with several of this year’s top-yielding Dow components already posting impressive gains.&nbsp;</p>



<h2 class="wp-block-heading">The Dogs of the Dow Are Having a Strong Year</h2>



<p class="wp-block-paragraph">Here’s a closer look at how the strategy is performing as of Nov. 13, 2026:&nbsp;&nbsp;</p>



<ul id="block-a9213301-22cd-46ca-a750-d442ca2d775f" class="wp-block-list">
<li><strong><a href="https://stocksearning.com/stocks/VZ/earnings-date">Verizon (NYSE: VZ)</a></strong>, which yields 6.08%, ran from $39.48 to a current price of $46.55.</li>



<li><strong><a href="https://stocksearning.com/stocks/CVX/earnings-date">Chevron (NYSE: CVX)</a></strong>, which yields 3.29%, ran from $149.32 to $216.35.</li>



<li><strong><a href="https://stocksearning.com/stocks/MRK/earnings-date">Mer-95ck (NYSE: MRK)</a></strong>, which yields 2.31%, ran from about $104.01 to $146.95.</li>



<li><strong><a href="https://stocksearning.com/stocks/PG/earnings-date">Procter &amp; Gamble (NYSE: PG)</a></strong>, which yields 2.59%, ran from $141.04 to $168.</li>



<li><strong><a href="https://stocksearning.com/stocks/AMGN/earnings-date">Amgen (NASDAQ: AMGN)</a></strong>, which yields 2.16%, ran from $324.06 to $467.</li>



<li><strong><a href="https://stocksearning.com/stocks/KO/earnings-date">Coca-Cola (NYSE: KO)</a></strong>, which yields 2.18%, ran from $68.95 to $97.44.</li>



<li><strong><a href="https://stocksearning.com/stocks/NKE/earnings-date">Nike (NYSE: NKE)</a></strong>, which yields 4.34%, fell from $63.01 to $37.76</li>



<li><strong><a href="https://stocksearning.com/stocks/UNH/earnings-date">UnitedHealth (NYSE: UNH)</a></strong>, which yields 2.29%, ran from $326.43 to $405.13.</li>



<li><strong><a href="https://stocksearning.com/stocks/HD/earnings-date">Home Depot (NYSE: HD)</a></strong>, which yields 2.68%, ran from $338.61 to $348.26.</li>



<li><strong><a href="https://stocksearning.com/stocks/JNJ/earnings-date">Johnson &amp; Johnson (JNJ)</a></strong>, which yields 1.89%, ran from $204.55 to $283.52.</li>
</ul>



<p class="wp-block-paragraph">Not bad at all so far.</p>



<h2 class="wp-block-heading">Why This Strategy Still Works</h2>



<p class="wp-block-paragraph">Historically, the Dogs of the Dow do very well.</p>



<p class="wp-block-paragraph">The 2025 Dogs of the Dow outperformed the Dow Jones Industrial Average of 14.92% and the S&amp;P 500’s return of 17.88%, with a return of 18.91%.&nbsp;</p>



<p class="wp-block-paragraph">The&nbsp;2024 Dogs of the Dow&nbsp;underperformed the major indices in 2024. However, with dividends, investors still did well for the year. The&nbsp;2023 Dogs of the Dow&nbsp;returned an average of 10.1%, which came in below the 14.4% return on the Dow Jones’ Industrials. Still, with the appreciation in most of the 2023 Dogs coupled with dividends, investors still did well overall.</p>



<p class="wp-block-paragraph">The&nbsp;2022 Dogs of the Dow&nbsp;beat the major indices, even in a rough year. In fact, while the Dogs of the Dow stocks fell 1.6% on the year, once you add in the dividend payouts, the Dogs returned 2% on the year.&nbsp;And while 2% may not sound like a big win, consider that, in 2022, one of the worst years on record since 2008, the NASDAQ lost 33%.&nbsp; The S&amp;P 500 lost 19%.&nbsp; The Dow Jones lost about 9%.</p>



<p class="wp-block-paragraph">In 2021, the Dogs of the Dow returned about 16.3%. While 2020 wasn’t a great year for the Dogs, most other years have done very well.&nbsp; In 2019, the Dogs were up 20%.&nbsp; In 2018, they were up about 1%, but still beat the Dow, which fell close to 6%.&nbsp; In 2017, the Dogs were up 19%.&nbsp; In 2016, they were up 16%.</p>



<h2 class="wp-block-heading">A Simple Strategy for Long-Term Wealth</h2>



<p class="wp-block-paragraph">The appeal of the Dogs of the Dow comes down to simplicity. Investors get a straightforward way to focus on established businesses, collect dividends, and give out-of-favor stocks time to recover. There’s no need to predict the next hot sector or chase whatever happens to be leading the market.</p>



<p class="wp-block-paragraph">Of course, a high dividend yield doesn’t automatically make a stock a bargain. A falling share price can signal real business problems, and dividend payments aren’t guaranteed. The strategy can also lag the broader market, sometimes for extended periods. That makes patience and realistic expectations essential.</p>



<p class="wp-block-paragraph">Still, building wealth doesn’t always require a complicated approach. For investors who value income and a disciplined annual routine, the Dogs of the Dow offer a strategy worth understanding. The goal is to let dividends and potential share-price recoveries work together over time—and stay focused beyond any single year’s results.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://cms.stocksearning.com/2026/11/update-2026-dogs-of-the-dow-strategy-2/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>An Update on the 2026 Dogs of the Dow Strategy</title>
		<link>https://cms.stocksearning.com/2026/10/update-2026-dogs-of-the-dow-strategy/</link>
					<comments>https://cms.stocksearning.com/2026/10/update-2026-dogs-of-the-dow-strategy/#respond</comments>
		
		<dc:creator><![CDATA[Ian Cooper]]></dc:creator>
		<pubDate>Mon, 12 Oct 2026 20:00:00 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[HD]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[KO]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[NKE]]></category>
		<category><![CDATA[PG]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[VZ]]></category>
		<guid isPermaLink="false">https://cms.stocksearning.com/?p=8944</guid>

					<description><![CDATA[For investors looking to build wealth with blue-chip dividend stocks, few strategies have stood the test of time like the Dogs of the Dow. ]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">For investors looking to build wealth with blue-chip dividend stocks, few strategies have stood the test of time like the&nbsp;<a href="https://www.dogsofthedow.com/" target="_blank" rel="noopener">Dogs of the Dow</a>.&nbsp;The simple approach focuses on buying the 10 highest-yielding stocks in the Dow Jones Industrial Average at the beginning of each year and holding them for 12 months.</p>



<div class="wp-block-rank-math-toc-block" id="rank-math-toc"><h2>Table of Contents</h2><nav><ul><li><a href="#the-dogs-of-the-dow-are-having-a-strong-year">The Dogs of the Dow Are Having a Strong Year</a></li><li><a href="#why-this-strategy-still-works">Why This Strategy Still Works</a></li><li><a href="#a-simple-strategy-for-long-term-wealth">A Simple Strategy for Long-Term Wealth</a></li></ul></nav></div>



<p class="wp-block-paragraph">Historically, the strategy has generated competitive returns, strong dividend income, and downside protection during volatile markets.&nbsp;After another solid showing in 2025, the Dogs of the Dow are once again proving their value in 2026, with several of this year’s top-yielding Dow components already posting impressive gains.&nbsp;</p>



<h2 id="the-dogs-of-the-dow-are-having-a-strong-year" class="wp-block-heading">The Dogs of the Dow Are Having a Strong Year</h2>



<p class="wp-block-paragraph">Here’s a closer look at how the strategy is performing as of Oct. 12, 2026:&nbsp;&nbsp;</p>



<ul class="wp-block-list">
<li><strong><a href="https://stocksearning.com/stocks/VZ/earnings-date">Verizon (NYSE: VZ)</a></strong>, which yields 6.79%, ran from $39.48 to a current price of $41.65&nbsp;</li>



<li><strong><a href="https://stocksearning.com/stocks/CVX/earnings-date">Chevron (NYSE: CVX)</a></strong>, which yields 3.36%, ran from $149.32 to $212.</li>



<li><strong><a href="https://stocksearning.com/stocks/MRK/earnings-date">Merck (NYSE: MRK)</a></strong>, which yields 2.34%, ran from about $104.01 to $145.60.</li>



<li><strong><a href="https://stocksearning.com/stocks/PG/earnings-date">Procter &amp; Gamble (NYSE: PG)</a></strong>, which yields 2.88%, ran from $141.04 to $151.23.</li>



<li><strong><a href="https://stocksearning.com/stocks/AMGN/earnings-date">Amgen (NASDAQ: AMGN)</a></strong>, which yields 2.43%, ran from $324.06 to $414.87.</li>



<li><strong><a href="https://stocksearning.com/stocks/KO/earnings-date">Coca-Cola (NYSE: KO)</a></strong>, which yields 2.41%, ran from $68.95 to $88.05.</li>



<li><strong><a href="https://stocksearning.com/stocks/NKE/earnings-date">Nike (NYSE: NKE)</a></strong>, which yields 4.72%, fell from $63.01 to $34.71.</li>



<li><strong><a href="https://stocksearning.com/stocks/UNH/earnings-date">UnitedHealth (NYSE: UNH)</a></strong>, which yields 2.45%, ran from $326.43 to $379.30.</li>



<li><strong><a href="https://stocksearning.com/stocks/HD/earnings-date">Home Depot (NYSE: HD)</a></strong>, which yields 3.21%, fell from $338.61 to $290.74.</li>



<li><strong><a href="https://stocksearning.com/stocks/JNJ/earnings-date">Johnson &amp; Johnson (JNJ)</a></strong>, which yields 2.59%, ran from $204.55 to $261.44.</li>
</ul>



<p class="wp-block-paragraph">Not bad at all so far.</p>



<h2 id="why-this-strategy-still-works" class="wp-block-heading">Why This Strategy Still Works</h2>



<p class="wp-block-paragraph">Historically, the Dogs of the Dow do very well.</p>



<p class="wp-block-paragraph">The 2025 Dogs of the Dow outperformed the Dow Jones Industrial Average of 14.92% and the S&amp;P 500’s return of 17.88%, with a return of 18.91%.&nbsp;</p>



<p class="wp-block-paragraph">The&nbsp;2024 Dogs of the Dow&nbsp;underperformed the major indices in 2024. However, with dividends, investors still did well for the year. The&nbsp;2023 Dogs of the Dow&nbsp;returned an average of 10.1%, which came in below the 14.4% return on the Dow Jones’ Industrials. Still, with the appreciation in most of the 2023 Dogs coupled with dividends, investors still did well overall.</p>



<p class="wp-block-paragraph">The&nbsp;2022 Dogs of the Dow&nbsp;beat the major indices, even in a rough year. In fact, while the Dogs of the Dow stocks fell 1.6% on the year, once you add in the dividend payouts, the Dogs returned 2% on the year.&nbsp;And while 2% may not sound like a big win, consider that, in 2022, one of the worst years on record since 2008, the NASDAQ lost 33%.&nbsp; The S&amp;P 500 lost 19%.&nbsp; The Dow Jones lost about 9%.</p>



<p class="wp-block-paragraph">In 2021, the Dogs of the Dow returned about 16.3%. While 2020 wasn’t a great year for the Dogs, most other years have done very well.&nbsp; In 2019, the Dogs were up 20%.&nbsp; In 2018, they were up about 1%, but still beat the Dow, which fell close to 6%.&nbsp; In 2017, the Dogs were up 19%.&nbsp; In 2016, they were up 16%.</p>



<h2 id="a-simple-strategy-for-long-term-wealth" class="wp-block-heading">A Simple Strategy for Long-Term Wealth</h2>



<p class="wp-block-paragraph">The appeal of the Dogs of the Dow comes down to simplicity. Investors get a straightforward way to focus on established businesses, collect dividends, and give out-of-favor stocks time to recover. There’s no need to predict the next hot sector or chase whatever happens to be leading the market.</p>



<p class="wp-block-paragraph">Of course, a high dividend yield doesn’t automatically make a stock a bargain. A falling share price can signal real business problems, and dividend payments aren’t guaranteed. The strategy can also lag the broader market, sometimes for extended periods. That makes patience and realistic expectations essential.</p>



<p class="wp-block-paragraph">Still, building wealth doesn’t always require a complicated approach. For investors who value income and a disciplined annual routine, the Dogs of the Dow offer a strategy worth understanding. The goal is to let dividends and potential share-price recoveries work together over time—and stay focused beyond any single year’s results.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://cms.stocksearning.com/2026/10/update-2026-dogs-of-the-dow-strategy/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>2 Pharmaceutical Stocks Positioned for the Next Growth Cycle</title>
		<link>https://cms.stocksearning.com/2026/09/pharmaceutical-stock-beyond-glp1/</link>
					<comments>https://cms.stocksearning.com/2026/09/pharmaceutical-stock-beyond-glp1/#respond</comments>
		
		<dc:creator><![CDATA[Chris Markoch]]></dc:creator>
		<pubDate>Tue, 22 Sep 2026 12:00:00 +0000</pubDate>
				<category><![CDATA[Evergreen]]></category>
		<category><![CDATA[ABBV]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[NVO]]></category>
		<guid isPermaLink="false">https://cms.stocksearning.com/?p=7895</guid>

					<description><![CDATA[For investors willing to look past the GLP-1 spotlight, MRK and ABBV offer exposure to the next chapter in pharmaceutical stocks,]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">The GLP-1 movement is alive and well. What started out as a fringe area of the pharmaceutical space is now as mainstream as it gets. Anything you watch or stream will probably have a commercial for one or more of the GLP-1 drugs in the market. It&#8217;s a huge market that continues to grow and is likely to do so for several years.&nbsp;&nbsp;</p>



<div class="wp-block-rank-math-toc-block" id="rank-math-toc"><h2>Table of Contents</h2><nav><ul><li><a href="#why-glp-1-drugs-have-become-mature">Why GLP-1 Drugs Have Become Mature </a></li><li><a href="#artificial-intelligence-is-the-pivot">Artificial Intelligence Is the Pivot </a></li><li><a href="#the-case-for-merck">Why Merck Stock Offers More Than Keytruda</a></li><li><a href="#the-case-for-abb-vie">Why AbbVie Stock Is Moving Beyond Humira</a></li><li><a href="#the-future-of-pharmaceutical-stocks">The Future of Pharmaceutical Stocks </a></li></ul></nav></div>



<p class="wp-block-paragraph">Yet, that hasn&#8217;t mattered much to the two biggest names in the sector. <a href="https://stocksearning.com/stocks/LLY/earnings-date" target="_blank" rel="noreferrer noopener"><strong>Eli Lilly (NYSE: LLY)</strong></a> is up 8.43% in 2026 as of the market close on Sept. 21. That&#8217;s&nbsp;below the S&amp;P 500 and far below the stock&#8217;s blistering performance over the last five years. Still, analysts remain bullish on LLY, due in part – but not completely – on its leadership in GLP-1.&nbsp;</p>



<p class="wp-block-paragraph">The situation with&nbsp;<a href="https://stocksearning.com/stocks/NVO/earnings-date" target="_blank" rel="noreferrer noopener"><strong>Novo Nordisk (NYSE: NVO)</strong></a><strong>&nbsp;</strong>is not as bright. As of the market close on Sept. 21, NVO stock is down over 35% in the last 12 months, including over 21% in 2026. That makes the 55% stock price gain in the last five years less impressive.&nbsp;</p>



<p class="wp-block-paragraph">But what about the future? Biopharmaceutical investors may want to look beyond GLP-1 drugs. That&#8217;s a debate that seems to have been settled.&nbsp;</p>



<h2 id="why-glp-1-drugs-have-become-mature" class="wp-block-heading">Why GLP-1 Drugs Have Become Mature&nbsp;</h2>



<p class="wp-block-paragraph">GLP-1 is no longer a set-it-and-forget-it growth story.&nbsp;The category is crowded now. Novo and Lilly face pricing pressure from insurers and pharmacy benefit managers, plus a growing list of oral and injectable competitors working their way through trials. &nbsp;</p>



<p class="wp-block-paragraph">Perception hasn&#8217;t caught up to that shift. Investors still treat GLP-1 exposure as an automatic winner, but the market has started pricing in deceleration, not acceleration. It&#8217;s becoming more difficult for drugmakers to differentiate themselves either by indication or dosage.&nbsp;&nbsp;</p>



<p class="wp-block-paragraph">This isn&#8217;t about the current GLP-1 drugs being effective. The question for investors is how to make them better, and that&#8217;s proving to be difficult.&nbsp;&nbsp;</p>



<h2 id="artificial-intelligence-is-the-pivot" class="wp-block-heading">Artificial Intelligence Is the Pivot&nbsp;</h2>



<p class="wp-block-paragraph">So, where is the capital rotating? Artificial intelligence (AI) has become the dominant growth narrative across every sector, and&nbsp;the pharmaceutical sector&nbsp;is no exception. Drugmakers using AI to compress trial timelines and cut discovery costs are attracting fresh investor attention.&nbsp;</p>



<p class="wp-block-paragraph">That shift matters for two reasons. First, it&#8217;s pulling speculative dollars away from GLP-1 as the default biotech trade. Second, it&#8217;s rewarding companies with diversified pipelines over single-drug bets. Merck and AbbVie fit that description. Neither depends on obesity drugs for its growth story, and both have leaned into AI-assisted drug development.&nbsp;</p>



<h2 id="the-case-for-merck" class="wp-block-heading">Why Merck Stock Offers More Than Keytruda</h2>



<p class="wp-block-paragraph"><a href="https://stocksearning.com/stocks/mrk/earnings-date" target="_blank" rel="noreferrer noopener"><strong>Merck (NYSE: MRK)</strong></a><strong> </strong>built its 2026 story around Keytruda, its flagship oncology drug. <a href="https://files.quartr.com/conference-calls/b149ce59ef8d94a89015b643dccc7dca-2026-08-04-10-51-03.pdf?ref=TWFya2V0QmVhdCBNZWRpYSBMTEM=" target="_blank" rel="noopener">Keytruda sales grew in the high single digits</a> in the first half of the year, and management has guided toward tens of billions in new commercial opportunities by the mid-2030s. The stock has rallied sharply off its 2025 lows, moving from roughly $110 in January to well above $140 by late summer.&nbsp;</p>



<figure class="wp-block-image size-large"><img fetchpriority="high" decoding="async" width="600" height="343" data-source="article-image" src="https://cms.stocksearning.com/wp-content/uploads/2026/09/MRK_02-600x343.png" alt="pharmaceutical - StockEarnings" class="wp-image-7899" srcset="https://cms.stocksearning.com/wp-content/uploads/2026/09/MRK_02-600x343.png 600w, https://cms.stocksearning.com/wp-content/uploads/2026/09/MRK_02-300x171.png 300w, https://cms.stocksearning.com/wp-content/uploads/2026/09/MRK_02-768x439.png 768w, https://cms.stocksearning.com/wp-content/uploads/2026/09/MRK_02.png 1287w" sizes="(max-width: 600px) 100vw, 600px" /></figure>



<p class="wp-block-paragraph">That&#8217;s the fundamentals side.&nbsp;But until 2026,&nbsp;perception lagged behind. Investors spent much of last year fixated on Keytruda&#8217;s looming patent cliff, treating Merck as a one-drug company facing a cliff edge. &nbsp;</p>



<p class="wp-block-paragraph">That framing undersold the pipeline. WINREVAIR and OHTUVAYRE are scaling. New oncology combinations, including a lung cancer therapy developed with a Chinese partner, are showing strong late-stage results. Merck also priced $6 billion in debt this spring to maintain funding for pipeline investments. That&#8217;s a&nbsp;sign that management sees more runway ahead.&nbsp;</p>



<p class="wp-block-paragraph">MRK stock&nbsp;still trades at a discount to peers on a forward basis. Analysts have been raising price targets throughout the year as the <a href="https://cms.stocksearning.com/2026/08/merck-and-moderna-cancer-vaccine/">pipeline story firms up</a>. That&#8217;s&nbsp;a&nbsp;pattern&nbsp;that income and growth investors should recognize.&nbsp;</p>



<figure class="wp-block-image size-large"><img decoding="async" width="600" height="312" data-source="article-image" src="https://cms.stocksearning.com/wp-content/uploads/2026/09/MRK_2026-09-21_19-33-16-600x312.png" alt="pharmaceutical - StockEarnings" class="wp-image-7897" srcset="https://cms.stocksearning.com/wp-content/uploads/2026/09/MRK_2026-09-21_19-33-16-600x312.png 600w, https://cms.stocksearning.com/wp-content/uploads/2026/09/MRK_2026-09-21_19-33-16-300x156.png 300w, https://cms.stocksearning.com/wp-content/uploads/2026/09/MRK_2026-09-21_19-33-16-768x400.png 768w, https://cms.stocksearning.com/wp-content/uploads/2026/09/MRK_2026-09-21_19-33-16.png 1160w" sizes="(max-width: 600px) 100vw, 600px" /></figure>



<h2 id="the-case-for-abb-vie" class="wp-block-heading">Why AbbVie Stock Is Moving Beyond Humira</h2>



<p class="wp-block-paragraph"><a href="https://stocksearning.com/stocks/abbv/earnings-date" target="_blank" rel="noreferrer noopener"><strong>AbbVie (NYSE: ABBV)</strong></a><strong> </strong>faced its own version of the single-drug fear. Humira, once the world&#8217;s best-selling drug, lost U.S. patent exclusivity in 2023. The market treated that loss of exclusivity as an existential threat. It wasn&#8217;t.&nbsp;</p>



<p class="wp-block-paragraph">Skyrizi and Rinvoq, AbbVie&#8217;s next-generation immunology drugs, have <a href="https://cms.stocksearning.com/2026/05/abbvie-q1-earnings-record-growth/">more than replaced what Humira lost</a>. Combined sales topped $25 billion in 2025 and are on pace to clear $31 billion in 2026, ahead of management&#8217;s own prior guidance. Skyrizi alone is capturing roughly three-quarters of new frontline patient starts in inflammatory bowel disease. Humira&#8217;s decline, meanwhile, has become a footnote rather than a headline.&nbsp;</p>



<p class="wp-block-paragraph">Normalized earnings per share bottomed near $10 in 2025 after falling from nearly $14 in 2022. The Street now models a sharp rebound, with EPS climbing back toward that prior peak in 2026 and continuing higher from there. AbbVie&#8217;s neuroscience segment is also compounding at double-digit growth. The stock has been volatile in 2026, but the underlying business looks stronger than the price action suggests.&nbsp;</p>



<figure class="wp-block-image size-large"><img decoding="async" width="600" height="312" data-source="article-image" src="https://cms.stocksearning.com/wp-content/uploads/2026/09/ABBV_2026-09-21_19-33-50-600x312.png" alt="pharmaceutical - StockEarnings" class="wp-image-7898" srcset="https://cms.stocksearning.com/wp-content/uploads/2026/09/ABBV_2026-09-21_19-33-50-600x312.png 600w, https://cms.stocksearning.com/wp-content/uploads/2026/09/ABBV_2026-09-21_19-33-50-300x156.png 300w, https://cms.stocksearning.com/wp-content/uploads/2026/09/ABBV_2026-09-21_19-33-50-768x400.png 768w, https://cms.stocksearning.com/wp-content/uploads/2026/09/ABBV_2026-09-21_19-33-50.png 1160w" sizes="(max-width: 600px) 100vw, 600px" /></figure>



<h2 id="the-future-of-pharmaceutical-stocks" class="wp-block-heading">The Future of Pharmaceutical Stocks&nbsp;</h2>



<p class="wp-block-paragraph">Perception and fundamentals rarely move in lockstep, and that gap is where opportunity tends to hide. GLP-1 stocks still dominate pharma headlines, but Lilly and Novo&nbsp;Nordisk&#8217;s stock performance in 2026 hasn&#8217;t matched the hype. &nbsp;</p>



<p class="wp-block-paragraph">Merck and AbbVie tell a different story. Both weathered a narrative of decline tied to a single blockbuster drug, and both have since rebuilt their growth cases around diversified, less obvious pipelines. For investors willing to look past the GLP-1 spotlight, MRK and ABBV offer exposure to the next chapter in pharmaceutical stocks, one where AI-driven pipeline execution, not a single weight-loss drug, decides who wins.&nbsp;</p>
]]></content:encoded>
					
					<wfw:commentRss>https://cms.stocksearning.com/2026/09/pharmaceutical-stock-beyond-glp1/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Pfizer’s Personalized Medicine Strategy Looks Ready to Pay Off</title>
		<link>https://cms.stocksearning.com/2026/08/pfizer-personalized-medicine-play/</link>
					<comments>https://cms.stocksearning.com/2026/08/pfizer-personalized-medicine-play/#respond</comments>
		
		<dc:creator><![CDATA[Chris Markoch]]></dc:creator>
		<pubDate>Fri, 21 Aug 2026 13:45:00 +0000</pubDate>
				<category><![CDATA[Evergreen]]></category>
		<category><![CDATA[BNTX]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[mrna]]></category>
		<category><![CDATA[PFE]]></category>
		<guid isPermaLink="false">https://cms.stocksearning.com/?p=6161</guid>

					<description><![CDATA[For investors looking to play the personalized medicine theme, Pfizer offers a diversified pipeline, an oncology franchise, and a dividend yield near 6%. ]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">Personalized medicine is back in the headlines.&nbsp;<a href="https://stocksearning.com/stocks/MRK/earnings-date" target="_blank" rel="noreferrer noopener"><strong>Merck&nbsp;&amp; Co. (NYSE: MRK)</strong></a>&nbsp;and&nbsp;<a href="https://stocksearning.com/stocks/mrna" target="_blank" rel="noreferrer noopener"><strong>Moderna&nbsp;(NASDAQ: MRNA)</strong></a>&nbsp;announced this week that their experimental melanoma vaccine,&nbsp;intismeran, hit its main goals in a large Phase 3 trial. Combined with Merck&#8217;s Keytruda, the mRNA-based shot slowed cancer recurrence and reduced the risk of&nbsp;the disease&nbsp;spreading.&nbsp;<a href="https://cms.stocksearning.com/2026/08/merck-and-moderna-cancer-vaccine/" target="_blank" rel="noreferrer noopener">Moderna&#8217;s stock jumped</a>, and Merck shares climbed too.&nbsp;</p>



<div class="wp-block-rank-math-toc-block" id="rank-math-toc"><h2>Table of Contents</h2><nav><ul><li><a href="#how-ai-is-powering-the-personalized-medicine-shift">How AI Is Powering the Personalized Medicine Shift </a></li><li><a href="#pfizers-deep-bench-in-precision-oncology">Pfizer&#8217;s Deep Bench in Precision Oncology </a></li><li><a href="#what-the-charts-say-about-pfe-right-now">What the Charts Say About PFE Right Now </a></li><li><a href="#a-dividend-that-rewards-investors-who-wait">A Dividend That Rewards Investors Who Wait </a></li></ul></nav></div>



<p class="wp-block-paragraph">The news reignited&nbsp;investor&nbsp;interest in a theme&nbsp;that&#8217;s&nbsp;been building for years: using genetic and molecular data to design treatments tailored to individual patients. Moderna supplied the mRNA technology. Merck brought commercial muscle and its blockbuster immunotherapy. Together, they may have proven that personalized cancer vaccines&nbsp;may&nbsp;actually work.&nbsp;</p>



<p class="wp-block-paragraph"><a href="https://stocksearning.com/stocks/PFE/earnings-date" target="_blank" rel="noreferrer noopener"><strong>Pfizer&nbsp;(NYSE: PFE)</strong></a>&nbsp;wasn&#8217;t&nbsp;part of this week&#8217;s announcement. But&nbsp;it&#8217;s&nbsp;been quietly building its own case in personalized and precision medicine for years, particularly in oncology. The company has adopted a formal precision-medicine framework for drug development, invested heavily in genomic data, and spent&nbsp;$43 billion&nbsp;acquiring&nbsp;Seagen&#8217;s&nbsp;antibody-drug conjugate platform.&nbsp;</p>



<p class="wp-block-paragraph">For investors looking to play the broader personalized medicine theme, Pfizer offers something Moderna and Merck don&#8217;t: a deep, diversified pipeline, a well-established oncology franchise, and a dividend yield near 6%. That combination makes PFE worth a closer look, even if it isn&#8217;t the company making this week&#8217;s splashy headlines.&nbsp;</p>



<p class="wp-block-paragraph">The stock has also quietly turned higher. Shares are up&nbsp;nearly 4%&nbsp;over the past week and have climbed off their summer lows. That move, paired with&nbsp;<a href="https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/" target="_blank" rel="noreferrer noopener">this week&#8217;s industry news</a>,&nbsp;makes now&nbsp;a good time&nbsp;to revisit Pfizer&#8217;s personalized medicine story.&nbsp;</p>



<h2 id="how-ai-is-powering-the-personalized-medicine-shift" class="wp-block-heading">How AI Is Powering the Personalized Medicine Shift&nbsp;</h2>



<p class="wp-block-paragraph">Biotech&nbsp;has become attractive to&nbsp;investors looking for an alternative to the frothy AI infrastructure trade. But that framing misses something. Biotech&nbsp;isn&#8217;t&nbsp;really an alternative to AI. It may be one of the best ways to invest in AI for the next decade.&nbsp;</p>



<p class="wp-block-paragraph">AI&#8217;s strengths line up well with biotech&#8217;s biggest bottleneck. Drugs take years to reach the market. Even before that, they&nbsp;must&nbsp;survive clinical trials, where most candidates fail. That slow, expensive process is exactly where AI can help most.&nbsp;</p>



<p class="wp-block-paragraph">Personalized medicine depends on data. Lots of it. Genomic sequencing, proteomics, and real-world patient outcomes all need to be analyzed at&nbsp;a massive&nbsp;scale to&nbsp;identify&nbsp;what makes one patient&#8217;s cancer different from another&#8217;s.&nbsp;That&#8217;s&nbsp;where artificial intelligence comes in.&nbsp;</p>



<p class="wp-block-paragraph">AI models can now scan genetic and molecular data far faster than traditional methods. This lets researchers spot patterns tied to specific mutations. It also speeds up early drug discovery, helping companies match compounds to the patients most likely to&nbsp;benefit&nbsp;from them.&nbsp;</p>



<p class="wp-block-paragraph">The result is a shift in how trials are designed. Instead of testing one drug on a broad population, companies increasingly use AI to enroll patients whose tumors carry a specific genetic signature. That improves the odds a trial succeeds, and&nbsp;it&#8217;s&nbsp;part of why&nbsp;intismeran&#8217;s&nbsp;melanoma results mattered so much this week. It&nbsp;signals that&nbsp;AI-assisted precision approaches are starting to deliver.&nbsp;</p>



<p class="wp-block-paragraph">AI also plays a growing role after a drug reaches the market. Companies now use predictive analytics to match approved therapies to the patients most likely to respond. For a pharmaceutical company, that kind of AI infrastructure&nbsp;isn&#8217;t&nbsp;a side project.&nbsp;It&#8217;s&nbsp;becoming the backbone of how new medicines get discovered, tested, and delivered to the right patients.&nbsp;</p>



<h2 id="pfizers-deep-bench-in-precision-oncology" class="wp-block-heading">Pfizer&#8217;s Deep Bench in Precision Oncology&nbsp;</h2>



<p class="wp-block-paragraph">Pfizer has pursued personalized medicine through a different route than Moderna. Rather than betting big on a single mRNA vaccine platform, Pfizer has built a&nbsp;<a href="https://www.pfizer.com/science/drug-product-pipeline" target="_blank" rel="noreferrer noopener">broad, multi-modality oncology pipeline</a>. It includes small molecules, biologics, and antibody-drug conjugates gained through its 2023&nbsp;Seagen&nbsp;acquisition.&nbsp;</p>



<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="600" height="271" data-source="article-image" src="https://cms.stocksearning.com/wp-content/uploads/2026/08/PFE_2-600x271.png" alt="personalized medicine - StockEarnings" class="wp-image-6163" srcset="https://cms.stocksearning.com/wp-content/uploads/2026/08/PFE_2-600x271.png 600w, https://cms.stocksearning.com/wp-content/uploads/2026/08/PFE_2-300x136.png 300w, https://cms.stocksearning.com/wp-content/uploads/2026/08/PFE_2-768x347.png 768w, https://cms.stocksearning.com/wp-content/uploads/2026/08/PFE_2-1536x694.png 1536w, https://cms.stocksearning.com/wp-content/uploads/2026/08/PFE_2.png 1903w" sizes="auto, (max-width: 600px) 100vw, 600px" /></figure>



<p class="wp-block-paragraph">That deal added four approved ADCs, including&nbsp;Padcev, which grew 13% last quarter on strong demand&nbsp;in&nbsp;bladder cancer. Oncology now makes up&nbsp;roughly 27%&nbsp;of Pfizer&#8217;s total revenue. As of early August, the company had 31 oncology, immunology, vaccine, and internal medicine candidates in Phase 3 trials, out of 95 total pipeline projects.&nbsp;</p>



<p class="wp-block-paragraph">Pfizer has also leaned into AI-driven drug discovery, using tools to analyze genomic and proteomic data at scale. The company has used AI in pharmacovigilance since 2014, well before it became an industry buzzword. Management has said it expects eight or more blockbuster oncology medicines in its portfolio by 2030, a target that leans heavily on precision approaches.&nbsp;</p>



<p class="wp-block-paragraph">Pfizer&nbsp;isn&#8217;t&nbsp;chasing the mRNA cancer vaccine race directly. But its&nbsp;<a href="https://stocksearning.com/stocks/BNTX/earnings-date" target="_blank" rel="noreferrer noopener"><strong>BioNTech&nbsp;(NASDAQ: BNTX)</strong></a>&nbsp;partnership on Covid-19 gave it firsthand experience scaling mRNA manufacturing. That&nbsp;know-how, paired with&nbsp;Seagen&#8217;s&nbsp;targeted ADC science, gives Pfizer multiple paths into personalized oncology. Investors get diversification that&nbsp;single platform&nbsp;biotech&#8217;s&nbsp;like Moderna&nbsp;can&#8217;t&nbsp;offer.&nbsp;</p>



<h2 id="what-the-charts-say-about-pfe-right-now" class="wp-block-heading">What the Charts Say About PFE Right Now&nbsp;</h2>



<p class="wp-block-paragraph">Pfizer&#8217;s daily chart shows&nbsp;a stock&nbsp;in recovery mode. Shares&nbsp;have climbed&nbsp;from&nbsp;roughly $23&nbsp;in July to&nbsp;nearly $28, breaking above the 200-day moving average. The MACD indicator has turned solidly bullish, suggesting momentum is building.&nbsp;</p>



<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="600" height="312" data-source="article-image" src="https://cms.stocksearning.com/wp-content/uploads/2026/08/PFE_2026-08-20_16-06-20-600x312.png" alt="personalized medicine - StockEarnings" class="wp-image-6164" srcset="https://cms.stocksearning.com/wp-content/uploads/2026/08/PFE_2026-08-20_16-06-20-600x312.png 600w, https://cms.stocksearning.com/wp-content/uploads/2026/08/PFE_2026-08-20_16-06-20-300x156.png 300w, https://cms.stocksearning.com/wp-content/uploads/2026/08/PFE_2026-08-20_16-06-20-768x400.png 768w, https://cms.stocksearning.com/wp-content/uploads/2026/08/PFE_2026-08-20_16-06-20.png 1160w" sizes="auto, (max-width: 600px) 100vw, 600px" /></figure>



<p class="wp-block-paragraph">The longer-term picture tells a different story. Pfizer&#8217;s all-time high was $61.71, set in December 2021 during the peak of Covid-19 vaccine demand. Even after this year&#8217;s rally, PFE trades more than 50% below that level. The company&nbsp;hasn&#8217;t&nbsp;found a replacement blockbuster since Comirnaty and Paxlovid sales&nbsp;faded.&nbsp;</p>



<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="600" height="312" data-source="article-image" src="https://cms.stocksearning.com/wp-content/uploads/2026/08/PFE_2026-08-20_16-06-34-600x312.png" alt="personalized medicine - StockEarnings" class="wp-image-6165" srcset="https://cms.stocksearning.com/wp-content/uploads/2026/08/PFE_2026-08-20_16-06-34-600x312.png 600w, https://cms.stocksearning.com/wp-content/uploads/2026/08/PFE_2026-08-20_16-06-34-300x156.png 300w, https://cms.stocksearning.com/wp-content/uploads/2026/08/PFE_2026-08-20_16-06-34-768x400.png 768w, https://cms.stocksearning.com/wp-content/uploads/2026/08/PFE_2026-08-20_16-06-34.png 1160w" sizes="auto, (max-width: 600px) 100vw, 600px" /></figure>



<p class="wp-block-paragraph">That gap is exactly why some investors see opportunity. A successful oncology pipeline, paired with the&nbsp;Metsera&nbsp;obesity assets&nbsp;acquired&nbsp;this year, could give Pfizer the growth catalyst&nbsp;it&#8217;s&nbsp;been missing since 2021.&nbsp;</p>



<h2 id="a-dividend-that-rewards-investors-who-wait" class="wp-block-heading">A Dividend That Rewards Investors Who Wait&nbsp;</h2>



<p class="wp-block-paragraph"><a href="https://stocksearning.com/stocks/PFE" target="_blank" rel="noreferrer noopener">Pfizer pays a $1.72 annual dividend&nbsp;per share</a>,&nbsp;good&nbsp;for a&nbsp;yield&nbsp;of approximately&nbsp;6%.&nbsp;That&#8217;s&nbsp;roughly&nbsp;double&nbsp;the yield on most large pharmaceutical stocks. The company has now paid 351 consecutive quarterly dividends, a streak dating back decades.&nbsp;</p>



<p class="wp-block-paragraph">The payout&nbsp;isn&#8217;t&nbsp;without risk. Pfizer&#8217;s free cash flow payout ratio has exceeded 100% in recent years, and the company faces a patent cliff for products like Eliquis later this decade. Still, management has repeatedly emphasized dividend stability as a core part of its capital allocation strategy.&nbsp;</p>



<p class="wp-block-paragraph">For investors willing to wait on Pfizer&#8217;s oncology pipeline to mature, that dividend offers a reason to stay patient. Personalized medicine may take years to fully reshape Pfizer&#8217;s growth story. In the meantime, the yield pays investors to hold on.&nbsp;</p>
]]></content:encoded>
					
					<wfw:commentRss>https://cms.stocksearning.com/2026/08/pfizer-personalized-medicine-play/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Merck and Moderna’s Cancer Vaccine Shows Substantial Promise </title>
		<link>https://cms.stocksearning.com/2026/08/merck-and-moderna-cancer-vaccine/</link>
					<comments>https://cms.stocksearning.com/2026/08/merck-and-moderna-cancer-vaccine/#respond</comments>
		
		<dc:creator><![CDATA[Ian Cooper]]></dc:creator>
		<pubDate>Wed, 19 Aug 2026 15:30:00 +0000</pubDate>
				<category><![CDATA[Evergreen]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[mrna]]></category>
		<guid isPermaLink="false">https://cms.stocksearning.com/?p=6012</guid>

					<description><![CDATA[Moderna and Merck’s personalized cancer vaccine shows promising melanoma results, potentially opening a new era of targeted cancer treatment.]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">An experimental cancer vaccine from <strong><a href="https://stocksearning.com/stocks/mrk">Merck (NYSE: MRK)</a></strong> and <strong><a href="https://stocksearning.com/stocks/mrna">Moderna (NASDAQ: MRNA)</a></strong> has shown positive results in a large, late-stage clinical trial, bringing the companies closer to potentially offering a new treatment for people with melanoma.</p>



<div class="wp-block-rank-math-toc-block" id="rank-math-toc"><h2>Table of Contents</h2><nav><ul><li><a href="#reportedly-the-vaccine-is-designed-specifically-for-each-patient">The Vaccine is Designed Specifically for Each Patient</a></li><li><a href="#however-the-trial-is-not-finished-yet">The Trial Is Not Finished Yet</a></li><li><a href="#how-does-the-personalized-vaccine-work">How Does the Personalized Vaccine Work?</a></li><li><a href="#what-comes-next">What Comes Next?</a></li></ul></nav></div>



<p class="wp-block-paragraph">At the moment, <a href="https://melanoma.org/facts-stats/" target="_blank" rel="noopener">about 1.4 million people currently live with melanoma in the U.S</a>. It’s also estimated that about 234,860 new U.S. cases could be diagnosed this year. We should also note that melanoma is one of the most serious types of skin cancer. It makes up only about 1% of skin cancer cases, but it causes most skin cancer deaths.</p>



<h2 id="reportedly-the-vaccine-is-designed-specifically-for-each-patient" class="wp-block-heading">The Vaccine is Designed Specifically for Each Patient</h2>



<p class="wp-block-paragraph">It <a href="https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/" target="_blank" rel="noopener">uses mRNA technology to teach the immune system</a> to recognize and attack cancer cells. The treatment is being tested alongside Merck’s Keytruda, a widely used cancer immunotherapy. The Phase 3 trial included more than 1,100 people with high-risk or advanced melanoma. All of the patients had surgery to remove all detectable cancer, but they still faced a high risk of the disease coming back.</p>



<p class="wp-block-paragraph">Researchers found that patients who received the personalized cancer vaccine along with Keytruda went longer without their melanoma returning than patients who received Keytruda alone. The combination also reduced the risk of the cancer spreading to other parts of the body.</p>



<p class="wp-block-paragraph">“It’s a big moment for medicine, a big moment for patients,” Moderna CEO Stephane Bancel said in an interview with CNBC.</p>



<h2 id="however-the-trial-is-not-finished-yet" class="wp-block-heading">The Trial Is Not Finished Yet</h2>



<p class="wp-block-paragraph">Researchers will continue to study whether the treatment helps patients live longer overall. Merck and Moderna also plan to present the full results at an upcoming medical meeting.</p>



<p class="wp-block-paragraph">In addition, the companies have not yet announced when they will ask U.S. regulators to approve the treatment. Dr. Dean Li, president of Merck Research Laboratories, said the companies expect to begin discussions with regulators about the treatment and its safety in the next few months.</p>



<p class="wp-block-paragraph">Dr. Jane Healy, Merck’s head of oncology early development, said the new treatment could provide patients with another option. She described the results as “very exciting” and said the treatment produced a meaningful improvement compared with Keytruda alone.</p>



<p class="wp-block-paragraph">The treatment was also generally well tolerated. Healy said the side effects were similar to those seen with other vaccines.</p>



<h2 id="how-does-the-personalized-vaccine-work" class="wp-block-heading">How Does the Personalized Vaccine Work?</h2>



<p class="wp-block-paragraph">One of the most interesting parts of the treatment is that the vaccine is made for each individual patient. Cancer cells can have different genetic mutations from one patient to another. Even two people with the same type of cancer may have tumors with very different characteristics. Merck and Moderna use information from a patient&#8217;s tumor to identify specific mutations that could be targeted. They then create a personalized mRNA vaccine designed to help the patient&#8217;s immune system recognize those cancer cells.</p>



<p class="wp-block-paragraph">The goal is to train the immune system to identify and destroy cancer cells that contain those specific markers. The vaccine is then given with Keytruda, which helps the immune system fight cancer by blocking a mechanism that cancer cells can use to hide from the body&#8217;s defenses. Together, the two treatments are designed to give the immune system a more powerful and targeted response. “We think&nbsp;[the results are]&nbsp;very meaningful for patients with this disease,” Healy said. She also suggested that the results could point to the potential of personalized cancer vaccines for other types of cancer.</p>



<h2 id="what-comes-next" class="wp-block-heading">What Comes Next?</h2>



<p class="wp-block-paragraph">The positive melanoma results are especially important for Moderna. The company is looking for new sources of growth beyond its COVID-19 vaccine business, and its cancer vaccine program has become an important part of that effort.</p>



<p class="wp-block-paragraph">Merck and Moderna are already studying the personalized vaccine in trials involving other cancers, including non-small cell lung cancer, bladder cancer and kidney cancer. The companies still have more work to do before the treatment could become widely available. Researchers need to finish the trial, study whether the treatment helps patients live longer and work with regulators on a possible approval.</p>



<p class="wp-block-paragraph">Still, the early results are an important step. If future studies continue to show benefits, personalized mRNA cancer vaccines could become a new way of treating cancer — with treatments designed around the unique characteristics of each patient&#8217;s tumor rather than using the same approach for everyone.</p>



<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="600" height="328" data-source="article-image" src="https://cms.stocksearning.com/wp-content/uploads/2026/08/MRNA_2026-08-19_10-31-22-600x328.png" alt="cancer vaccine-StockEarnings" class="wp-image-6023" srcset="https://cms.stocksearning.com/wp-content/uploads/2026/08/MRNA_2026-08-19_10-31-22-600x328.png 600w, https://cms.stocksearning.com/wp-content/uploads/2026/08/MRNA_2026-08-19_10-31-22-300x164.png 300w, https://cms.stocksearning.com/wp-content/uploads/2026/08/MRNA_2026-08-19_10-31-22-768x420.png 768w, https://cms.stocksearning.com/wp-content/uploads/2026/08/MRNA_2026-08-19_10-31-22.png 1382w" sizes="auto, (max-width: 600px) 100vw, 600px" /></figure>
]]></content:encoded>
					
					<wfw:commentRss>https://cms.stocksearning.com/2026/08/merck-and-moderna-cancer-vaccine/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Dogs of the Dow 2026: One of the Best Investment Strategies</title>
		<link>https://cms.stocksearning.com/2026/06/dogs-of-the-dow-investment-strategy/</link>
					<comments>https://cms.stocksearning.com/2026/06/dogs-of-the-dow-investment-strategy/#respond</comments>
		
		<dc:creator><![CDATA[Ian Cooper]]></dc:creator>
		<pubDate>Mon, 29 Jun 2026 19:15:00 +0000</pubDate>
				<category><![CDATA[Evergreen]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[CSCO]]></category>
		<category><![CDATA[CVZ]]></category>
		<category><![CDATA[HD]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[KO]]></category>
		<category><![CDATA[MCD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[NKE]]></category>
		<category><![CDATA[PG]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[VZ]]></category>
		<guid isPermaLink="false">https://cms.stocksearning.com/?p=2921</guid>

					<description><![CDATA[The Dogs of the Dow are off to another strong year. See why this time-tested dividend strategy continues to reward long-term investors.]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">For investors looking to build wealth with blue-chip dividend stocks, few strategies have stood the test of time like the&nbsp;Dogs of the Dow.&nbsp;</p>



<div class="wp-block-rank-math-toc-block" id="rank-math-toc"><h2>Table of Contents</h2><nav><ul><li><a href="#how-the-dogs-of-the-dow-performed-in-2025">How the Dogs of the Dow Performed in 2025</a></li><li><a href="#strong-start-in-2026">Dogs of the Dow Off to Strong Start in 2026</a></li><li><a href="#why-the-dogs-of-the-dow-strategy-still-works">Why this Strategy Still Works</a></li><li><a href="#in-short">The Long-Term Outlook</a></li></ul></nav></div>



<p class="wp-block-paragraph">The simple approach focuses on buying the 10 highest-yielding stocks in the Dow Jones Industrial Average at the beginning of each year and holding them for 12 months. Historically, the strategy has generated competitive returns, strong dividend income, and downside protection during volatile markets.&nbsp;</p>



<p class="wp-block-paragraph">After another solid showing in 2025, the Dogs of the Dow are once again proving their value in 2026, with several of this year&#8217;s top-yielding Dow components already posting impressive gains. Here&#8217;s a closer look at how the strategy performed last year, how it&#8217;s doing so far in 2026, and why income-focused investors continue to rely on this time-tested investing approach.</p>



<h2 id="how-the-dogs-of-the-dow-performed-in-2025" class="wp-block-heading">How the Dogs of the Dow Performed in 2025</h2>



<p class="wp-block-paragraph">For <a href="https://www.dogsofthedow.com/2025-dogs-of-the-dow.htm" target="_blank" rel="noopener">2025</a>, here’s how the Dogs of the Dow did.</p>



<ul class="wp-block-list">
<li><strong><a href="https://stocksearning.com/stocks/VZ/earnings-date">Verizon (NYSE: VZ)</a></strong> started 2025 at around $38. It ended the year at $39.44.</li>



<li><strong><a href="https://stocksearning.com/stocks/CVX/earnings-date">Chevron (NYSE: CVX)</a></strong> from about $142 to $149.56.</li>



<li><strong><a href="https://stocksearning.com/stocks/JNJ/earnings-date">Johnson &amp; Johnson (NYSE: JNJ)</a></strong> ran from $142 to $204.68.</li>



<li><strong><a href="https://stocksearning.com/stocks/AMGN/earnings-date">Amgen (NYSE: AMGN)</a></strong> ran from about $258 to $322.62.</li>



<li><strong><a href="https://stocksearning.com/stocks/MRK/earnings-date">Merck (NYSE: MRK)</a></strong> ran from about $98 to $103.74.</li>



<li><strong><a href="https://stocksearning.com/stocks/KO/earnings-date">Coca-Cola (NYSE: KO)</a></strong> jumped from $61 to $68.99.</li>



<li><a href="https://stocksearning.com/stocks/IBM/earnings-date"><strong>IBM (NYSE: IBM)</strong> </a>ran from about $215 to a $292.38.</li>



<li><strong><a href="https://stocksearning.com/stocks/CSCO/earnings-date">Cisco (NYSE: CSCO)</a></strong> ran from about $58 to $76.21.</li>



<li><strong><a href="https://stocksearning.com/stocks/MCD/earnings-date">McDonald’s (NYSE: MCD)</a></strong> ran from about $293 to $301.88.</li>



<li><a href="https://stocksearning.com/stocks/PG/earnings-date"><strong>Procter &amp; Gamble (NYSE: PG)</strong> </a>fell from about $264 to $141.24</li>
</ul>



<p class="wp-block-paragraph">That’s not bad at all.</p>



<p class="wp-block-paragraph">Plus, once you factor in the yields for each, the Dogs outperformed the Dow Jones.</p>



<h2 id="strong-start-in-2026" class="wp-block-heading">Dogs of the Dow Off to Strong Start in 2026</h2>



<p class="wp-block-paragraph">As for <a href="https://www.dogsofthedow.com/2026-dogs-of-the-dow.htm" target="_blank" rel="noopener">2026</a>, here’s how the Dogs of the Dow have performed to date.</p>



<ul class="wp-block-list">
<li>Verizon (VZ), which yields 6.51%, ran from $39.48 to a current price of $43.52.</li>



<li>Chevron (CVX), which yields 4.2%, ran from $149.32 to $169.15.</li>



<li>Merck (MRK), which yields 2.64%, ran from about $104.01 to $128.88.</li>



<li>Procter &amp; Gamble (PG), which yields 2.95%, ran from $141.04 to $147.81.</li>



<li>Amgen (AMGN), which yields 2.8%, ran from $324.06 to $359.76.</li>



<li>Coca-Cola (KO), which yields 2.57%, ran from $68.95 to $82.77.</li>



<li><strong><a href="https://stocksearning.com/stocks/NKE/earnings-date">Nike (NYSE: NKE)</a></strong>, which yields 3.98%, fell from $63.01 to $41.24.</li>



<li><strong><a href="https://stocksearning.com/stocks/UNH/earnings-date">UnitedHealth (NYSE: UNH)</a></strong>, which yields 2.22%, ran from $326.43 to $419.04.</li>



<li><strong><a href="https://stocksearning.com/stocks/HD/earnings-date">Home Depot (NYSE: HD)</a></strong>, which yields 2.67%, ran from $338.61 to $348.76.</li>



<li>Johnson &amp; Johnson (JNJ), which yields 2.09%, ran from $204.55 to $256.24.</li>
</ul>



<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="600" height="175" data-source="article-image" src="https://cms.stocksearning.com/wp-content/uploads/2026/06/image_2026-06-29_134445884-600x175.png" alt="dogs of the dow-StockEarnings" class="wp-image-2933" srcset="https://cms.stocksearning.com/wp-content/uploads/2026/06/image_2026-06-29_134445884-600x175.png 600w, https://cms.stocksearning.com/wp-content/uploads/2026/06/image_2026-06-29_134445884-300x88.png 300w, https://cms.stocksearning.com/wp-content/uploads/2026/06/image_2026-06-29_134445884-768x224.png 768w, https://cms.stocksearning.com/wp-content/uploads/2026/06/image_2026-06-29_134445884.png 1021w" sizes="auto, (max-width: 600px) 100vw, 600px" /></figure>



<h2 id="why-the-dogs-of-the-dow-strategy-still-works" class="wp-block-heading">Why this Strategy Still Works</h2>



<p class="wp-block-paragraph">Historically, the Dogs of the Dow do very well.</p>



<p class="wp-block-paragraph">The <a href="https://www.dogsofthedow.com/2024-dogs-of-the-dow.htm" target="_blank" rel="noopener">2024 Dogs of the Dow</a> underperformed the major indices in 2024. However, with dividends, investors still did well for the year.</p>



<p class="wp-block-paragraph">The <a href="https://www.dogsofthedow.com/2023-dogs-of-the-dow.htm" target="_blank" rel="noopener">2023 Dogs of the Dow</a> returned an average of 10.1%, which came in below the 14.4% return on the Dow Jones’ Industrials. Still, with the appreciation in most of the 2023 Dogs coupled with dividends, investors still did well overall.</p>



<p class="wp-block-paragraph">The <a href="https://www.dogsofthedow.com/2022-dogs-of-the-dow.htm" target="_blank" rel="noopener">2022 Dogs of the Dow</a> beat the major indices, even in a rough year.</p>



<p class="wp-block-paragraph">In fact, while the Dogs of the Dow stocks fell 1.6% on the year, once you add in the dividend payouts, the Dogs returned 2% on the year.&nbsp;And while 2% may not sound like a big win, consider that, in 2022, one of the worst years on record since 2008, the NASDAQ lost 33%.&nbsp; The S&amp;P 500 lost 19%.&nbsp; The Dow Jones lost about 9%.</p>



<p class="wp-block-paragraph">In 2021, the Dogs of the Dow returned about 16.3%. While 2020 wasn’t a great year for the Dogs, most other years have done very well.&nbsp; In 2019, the Dogs were up 20%.&nbsp; In 2018, they were up about 1%, but still beat the Dow, which fell close to 6%.&nbsp; In 2017, the dogs were up 19%.&nbsp; In 2016, they were up 16%.</p>



<h2 id="in-short" class="wp-block-heading">The Long-Term Outlook</h2>



<p class="wp-block-paragraph">With several of the 2026 Dogs already delivering solid gains and continuing to pay dependable dividends, the strategy remains an appealing option for investors seeking income, stability, and long-term growth. As always, diversification and patience are key, but for those looking for a straightforward, historically successful investing strategy, the Dogs of the Dow continue to earn their place in a well-balanced portfolio.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://cms.stocksearning.com/2026/06/dogs-of-the-dow-investment-strategy/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Avoid the Crowd with a Long Position in Pharma Giant Merck (MRK) Stock</title>
		<link>https://cms.stocksearning.com/2026/06/long-position-pharma-merck-stock/</link>
					<comments>https://cms.stocksearning.com/2026/06/long-position-pharma-merck-stock/#respond</comments>
		
		<dc:creator><![CDATA[Joshua Enomoto]]></dc:creator>
		<pubDate>Tue, 23 Jun 2026 12:00:00 +0000</pubDate>
				<category><![CDATA[Evergreen]]></category>
		<category><![CDATA[MRK]]></category>
		<guid isPermaLink="false">https://cms.stocksearning.com/?p=2604</guid>

					<description><![CDATA[While AI dominates headlines, Merck stock may present a compelling contrarian opportunity for investors and traders.]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">It’s one of the most surprising developments in politics: President Donald Trump, known for his outspoken views and no-nonsense approach to even the most delicate and controversial topics, basically relented. With the Iran conflict apparently coming to a close, this unexpected dynamic has significant implications for pharmaceutical giant <strong><a href="https://stocksearning.com/stocks/mrk/earnings-date">Merck (NYSE: MRK)</a></strong>.</p>



<div class="wp-block-rank-math-toc-block" id="rank-math-toc"><h2>Table of Contents</h2><nav><ul><li><a href="#volatility-skew-offers-key-insights-for-mrk-stock">Volatility Skew Offers Key Insights for MRK Stock</a></li><li><a href="#using-an-inductive-model-to-trade-merck-stock">Using an Inductive Model to Trade Merck Stock</a></li></ul></nav></div>



<p class="wp-block-paragraph">At first glance, MRK stock doesn’t appear to have much direct relevance to the Iran war, which threatened to drag the world into a catastrophic depression. However, now that the Trump administration has signaled that it takes the threat of Iran bringing the global economy to its knees seriously, the worst-case scenario is apparently behind us.</p>



<p class="wp-block-paragraph">Of course, we still must consider multiple variables in this situation. For one thing, both the U.S. and Iran can ultimately disagree on the performance of the underlying memorandum of understanding. If so, Trump may decide to pull the trigger again on military action. Further, Israel’s displeasure at the sudden peace agreement imposes a serious wrinkle on the discussion.</p>



<p class="wp-block-paragraph">Still, if we were to take the deal at face value, the U.S. has decided that a prolonged conflict with Iran wasn’t worth the economic and societal damage that would likely erupt. As such, previously popular equities have seen a dramatic resurgence of demand — and that may pull public money due to the ‘FOMO’ effect.</p>



<p class="wp-block-paragraph">It’s no secret that many astute investors would rather consider opportunities that haven’t attracted mass attention. After all, there’s always a risk that too much money going into one place may spark a bearish reaction as the weak hands blink first. That’s where MRK stock comes into the picture. At this point, with the spotlight focused squarely on artificial intelligence and other tech-related names, a company like Merck flies under the radar.</p>



<p class="wp-block-paragraph">On a year-to-date basis, MRK stock is relatively pedestrian, gaining a little over 8%. Over the trailing month, the security has lost 7% of value, potentially making it an intriguing prospect under the presupposition of mean reversion theory.</p>



<h2 class="wp-block-heading" id="volatility-skew-offers-key-insights-for-mrk-stock">Volatility Skew Offers Key Insights for MRK Stock</h2>



<p class="wp-block-paragraph">With a pharmaceutical company like Merck, much of its trading and investment prospect obviously lies with progress on its <a href="https://www.merck.com/research/product-pipeline/" target="_blank" rel="noopener">flagship pipelines</a>. That’s not something that’s easy to predict. But in the interim of these disclosure cycles, we can potentially exploit its technical rumblings.</p>



<p class="wp-block-paragraph">For options traders, one of the most useful tools to consider is the volatility skew. By definition, the skew showcases implied volatility (IV) across the strike price spectrum of a given options chain. Since IV represents the range of motion for a security at a select strike, a heightened volatility reading incentives traders to hedge the potential move.</p>



<p class="wp-block-paragraph">In other words, the skew represents an insurance market. At any given moment, a popular security is liable to move either up or down. Since traders aren’t prescient, they must pay a protection premium so that they’re not caught out. Generally speaking, for mature equities, this premium is concentrated on put options, since there’s a greater risk of such stocks losing value quickly rather than vice versa.</p>



<p class="wp-block-paragraph">Interestingly, though, for Merck stock, the skew features a pronounced “smile” that is unlike what you might usually find with blue chips. Basically, put IV for the near-term July 10 expiration date swings sharply higher at the right-side tail (lower strike price range). This dynamic possibly indicates that smart money traders are assigning at least some probability to a severe negative event.</p>



<p class="wp-block-paragraph">Still, that’s not the only prominent characteristic of the skew. On the left-hand tail, call IV rises robustly for further out-the-money (OTM) strikes. When looking at this angle, traders are evidently paying a heightened premium for upside convexity.</p>



<p class="wp-block-paragraph">Broadly speaking, the smart money wants to be protected from catastrophe but it also desires exposure to potential upside swings. More specifically, there’s not much insurance demand for “realistic” strikes or strikes near the plausible trading range of MRK stock. Instead, the protection is centered on the two tails.</p>



<p class="wp-block-paragraph">To be fair, the skew isn’t necessarily pounding the table on either side of the trade. However, it’s only natural for traders to hedge against downside amid the current geopolitical environment. Fortunately, as cooler heads prevail over the Iran conflict, there’s now demand for enhanced upside. It’s this new framework which I believe speculators may be able to exploit.</p>



<h2 class="wp-block-heading" id="using-an-inductive-model-to-trade-merck-stock">Using an Inductive Model to Trade Merck Stock</h2>



<p class="wp-block-paragraph">While the volatility skew doesn’t offer a hard probability regarding future outcomes, we can use an inductive model — a Markov simulation to be precise — to forecast potential results. What aroused my attention to MRK stock is that, unlike other securities, it has suffered a significant slowdown in momentum. Again, under mean reversion theory, we may expect MRK to bounce back.</p>



<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="600" height="247" data-source="article-image" src="https://cms.stocksearning.com/wp-content/uploads/2026/06/MRK-stock-fwd-distributions-600x247.png" alt="Merck-StockEarnings" class="wp-image-2605" srcset="https://cms.stocksearning.com/wp-content/uploads/2026/06/MRK-stock-fwd-distributions-600x247.png 600w, https://cms.stocksearning.com/wp-content/uploads/2026/06/MRK-stock-fwd-distributions-300x124.png 300w, https://cms.stocksearning.com/wp-content/uploads/2026/06/MRK-stock-fwd-distributions-768x317.png 768w, https://cms.stocksearning.com/wp-content/uploads/2026/06/MRK-stock-fwd-distributions.png 1189w" sizes="auto, (max-width: 600px) 100vw, 600px" /></figure>



<p class="wp-block-paragraph">Notably, in the last 10 weeks, MRK stock has only printed three up weeks, leading to a downward slope. Under this 3-7-D sequence, over the next 10 weeks, the security has a median tendency of ranging between $112.50 and $120 (assuming a starting price of $113.87, Friday’s close). This distribution represents a sizable variance over a random 10-week long position, which would typically range between $113 and $115.50.</p>



<p class="wp-block-paragraph">Even more enticing, over the next three weeks following a 3-7-D signal flashing, Merck stock has demonstrated a tendency of rising to approximately the $118 level (assuming the same aforementioned starting price). If this pattern were to materialize again, the 114/118 bull call spread expiring July 10 could be in play.</p>



<p class="wp-block-paragraph">Basically, this trade requires MRK stock to rise through the $118 strike at expiration. If so, the maximum payout would be over 56%. The net debit per spread would be $256. Although this is a bit on the pricey side, you’d be trading a quality blue chip that is statistically stable, given its 60-month beta of only 0.21.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://cms.stocksearning.com/2026/06/long-position-pharma-merck-stock/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Protect Your Portfolio with 3 High-Yielding Dividend ETFs</title>
		<link>https://cms.stocksearning.com/2026/04/protect-portfolio-with-dividend-etfs/</link>
					<comments>https://cms.stocksearning.com/2026/04/protect-portfolio-with-dividend-etfs/#respond</comments>
		
		<dc:creator><![CDATA[Ian Cooper]]></dc:creator>
		<pubDate>Mon, 27 Apr 2026 15:30:00 +0000</pubDate>
				<category><![CDATA[Evergreen]]></category>
		<category><![CDATA[ABBV]]></category>
		<category><![CDATA[AFL]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[AVGO]]></category>
		<category><![CDATA[BRK.B]]></category>
		<category><![CDATA[CAT]]></category>
		<category><![CDATA[CLX]]></category>
		<category><![CDATA[CSCO]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[GD]]></category>
		<category><![CDATA[HD]]></category>
		<category><![CDATA[HRL]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[KO]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[NOBL]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[PNR]]></category>
		<category><![CDATA[SCHD]]></category>
		<category><![CDATA[SCHV]]></category>
		<category><![CDATA[UPS]]></category>
		<category><![CDATA[wmt]]></category>
		<category><![CDATA[XOM]]></category>
		<guid isPermaLink="false">https://cms.stocksearning.com/?p=1793</guid>

					<description><![CDATA[In uncertain markets, dividend ETFs —especially those emphasizing companies with long histories of growing payouts—can help anchor your portfolio.]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">If you’re looking for safety—and income— dividend ETFs, showcasing Dividend Aristocrats and Dividend Kings, are a great place to start.</p>



<div class="wp-block-rank-math-toc-block" id="rank-math-toc"><h2>Table of Contents</h2><nav><ul><li><a href="#a-pure-play-on-dividend-aristocrats">A Pure Play on Dividend Aristocrats</a></li><li><a href="#low-cost-exposure-to-high-quality-value-stocks">Low-Cost Exposure to High-Quality Value Stocks</a></li><li><a href="#high-yield-meets-dividend-growth-discipline">High Yield Meets Dividend Growth Discipline</a></li><li><a href="#dividend-et-fs-offer-stability-in-any-market">Dividend ETFs Offer Stability in Any Market</a></li></ul></nav></div>



<p class="wp-block-paragraph">Dividend Aristocrats are widely considered some of the highest-quality companies in the market. To earn this title, a company must have increased its dividend payouts for at least 25 consecutive years. Dividend Kings take that standard even further. These elite companies have raised their dividends for 50 years or more, proving their resilience across multiple economic cycles.</p>



<p class="wp-block-paragraph">What makes these companies particularly compelling is their ability to perform in virtually any environment. Whether facing inflation, recessions, rising interest rates, market crashes, or economic booms, they have consistently rewarded shareholders with growing income. That kind of durability is rare—and valuable. It also reflects strong management teams, disciplined capital allocation, and business models built to withstand long-term pressure.</p>



<p class="wp-block-paragraph">Simply put, if a company can survive decades of economic uncertainty and still pay—and raise—dividends, it deserves attention.</p>



<p class="wp-block-paragraph">There’s just one drawback: there isn’t currently a dedicated ETF focused solely on Dividend Kings. That means investors looking for exposure must either purchase individual stocks or turn to ETFs that emphasize similar high-quality, dividend-growing companies.</p>



<p class="wp-block-paragraph">Here are three strong ETF options to consider.</p>



<h2 class="wp-block-heading" id="a-pure-play-on-dividend-aristocrats">A Pure Play on Dividend Aristocrats</h2>



<p class="wp-block-paragraph">The&nbsp;<strong>ProShares S&amp;P 500 Dividend Aristocrats ETF (BATS: NOBL)</strong>&nbsp;offers direct exposure to companies that have increased dividends for at least 25 consecutive years.</p>



<p class="wp-block-paragraph">With an expense ratio of 0.35% and a yield of approximately 2.05%, <a href="https://www.proshares.com/globalassets/proshares/fact-sheet/prosharesfactsheetnobl.pdf" target="_blank" rel="noopener">NOBL tracks the S&amp;P 500 Dividend Aristocrats Index</a>. The fund focuses on stable, high-quality businesses with long track records of dividend growth—many of which have been increasing payouts for 40 years or more.</p>



<p class="wp-block-paragraph">Its holdings include well-known companies such as&nbsp;<strong><a href="https://stocksearning.com/stocks/CAT/earnings-date">Caterpillar (NYSE: CAT)</a></strong>, <strong><a href="https://stocksearning.com/stocks/PNR/earnings-date">Pentair (NYSE: PNR)</a></strong>,&nbsp;<strong><a href="https://stocksearning.com/stocks/ABBV/earnings-date">AbbVie (NYSE: ABBV)</a></strong>,&nbsp;<strong><a href="https://stocksearning.com/stocks/AFL/earnings-date">Aflac (NYSE: AFL)</a></strong>,&nbsp;<strong><a href="https://stocksearning.com/stocks/GD/earnings-date">General Dynamics (NYSE: GD)</a></strong>,&nbsp;<a href="https://stocksearning.com/stocks/CLX/earnings-date"><strong>Clorox (NYSE: CLX</strong>)</a>,<strong>&nbsp;<a href="https://stocksearning.com/stocks/wmt/earnings-datehttps://stocksearning.com/stocks/wmt/earnings-date">Walmart (NASDAQ: WMT)</a></strong>, and&nbsp;<strong><a href="https://stocksearning.com/stocks/HRl/earnings-date">Hormel Foods (NYSE: HRL)</a></strong>.</p>



<p class="wp-block-paragraph">These companies have demonstrated consistent performance and income reliability, making NOBL a strong choice for conservative, income-focused investors.</p>



<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="600" height="312" data-source="article-image" src="https://cms.stocksearning.com/wp-content/uploads/2026/04/NOBL_2026-04-27_11-00-11-600x312.png" alt="dividend ETFs - StockEarnings" class="wp-image-1800" srcset="https://cms.stocksearning.com/wp-content/uploads/2026/04/NOBL_2026-04-27_11-00-11-600x312.png 600w, https://cms.stocksearning.com/wp-content/uploads/2026/04/NOBL_2026-04-27_11-00-11-300x156.png 300w, https://cms.stocksearning.com/wp-content/uploads/2026/04/NOBL_2026-04-27_11-00-11-768x400.png 768w, https://cms.stocksearning.com/wp-content/uploads/2026/04/NOBL_2026-04-27_11-00-11.png 1160w" sizes="auto, (max-width: 600px) 100vw, 600px" /></figure>



<h2 class="wp-block-heading" id="low-cost-exposure-to-high-quality-value-stocks">Low-Cost Exposure to High-Quality Value Stocks</h2>



<p class="wp-block-paragraph">Another solid option is the&nbsp;<strong>Schwab U.S. Large Cap Value ETF (NYSEARCA: SCHV)</strong>, which focuses on large-cap value stocks.</p>



<p class="wp-block-paragraph">SCHV stands out for its ultra-low expense ratio of just 0.04%, making it one of the most cost-effective ETFs available. It also offers a yield of about 1.85% and provides exposure to a diversified basket of financially strong companies.</p>



<p class="wp-block-paragraph">Top holdings include&nbsp;<strong><a href="https://stocksearning.com/stocks/BRK.B/earnings-date">Berkshire Hathaway (NYSE: BRK.B)</a></strong>,&nbsp;<strong><a href="https://stocksearning.com/stocks/jnj/earnings-date">Johnson &amp; Johnson (NYSE: JNJ)</a></strong>,&nbsp;<strong><a href="https://stocksearning.com/stocks/xom/earnings-date">Exxon Mobil (NYSE: XOM)</a></strong>,&nbsp;<strong><a href="https://stocksearning.com/stocks/JPM/earnings-date">JPMorgan Chase (NYSE: JPM)</a></strong>,&nbsp;<strong><a href="https://stocksearning.com/stocks/hd/earnings-date">Home Depot (NYSE: HD)</a></strong>,&nbsp;<strong>AbbVie</strong>,&nbsp;<strong><a href="https://stocksearning.com/stocks/PFE/earnings-date">Pfizer (NYSE: PFE)</a></strong>, and&nbsp;<strong><a href="https://stocksearning.com/stocks/mrk/earnings-date">Merck &amp; Co. (NYSE: MRK)</a></strong>. </p>



<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="600" height="312" data-source="article-image" src="https://cms.stocksearning.com/wp-content/uploads/2026/04/SCHV_2026-04-27_11-01-00-600x312.png" alt="dividend ETFs - StockEarnings" class="wp-image-1801" srcset="https://cms.stocksearning.com/wp-content/uploads/2026/04/SCHV_2026-04-27_11-01-00-600x312.png 600w, https://cms.stocksearning.com/wp-content/uploads/2026/04/SCHV_2026-04-27_11-01-00-300x156.png 300w, https://cms.stocksearning.com/wp-content/uploads/2026/04/SCHV_2026-04-27_11-01-00-768x400.png 768w, https://cms.stocksearning.com/wp-content/uploads/2026/04/SCHV_2026-04-27_11-01-00.png 1160w" sizes="auto, (max-width: 600px) 100vw, 600px" /></figure>



<h2 class="wp-block-heading" id="high-yield-meets-dividend-growth-discipline">High Yield Meets Dividend Growth Discipline</h2>



<p class="wp-block-paragraph">The&nbsp;<strong>Schwab U.S. Dividend Equity ETF (NYSEARCA: SCHD)</strong>&nbsp;is another popular choice among income investors. With an expense ratio of 0.06% and a yield of roughly 3.5%, SCHD tracks the Dow Jones U.S. Dividend 100 Index. The ETF focuses on companies with strong fundamentals, sustainable dividends, and a history of consistent payouts.</p>



<p class="wp-block-paragraph">Its holdings include industry leaders such as&nbsp;<strong><a href="https://stocksearning.com/stocks/amgn/earnings-date">Amgen (NASDAQ: AMGN)</a></strong>,&nbsp;<strong>AbbVie</strong>,&nbsp;<strong>Home Depot</strong>,&nbsp;<strong><a href="https://stocksearning.com/stocks/csco/earnings-date">Cisco Systems (NASDAQ; CSCO)</a></strong>,&nbsp;<strong><a href="https://stocksearning.com/stocks/avgo/earnings-date">Broadcom (NASDAQ: AVGO)</a></strong>,&nbsp;<strong><a href="https://stocksearning.com/stocks/cvx/earnings-date">Chevron Corporation (NYSE: CVX)</a></strong>,&nbsp;<strong><a href="https://stocksearning.com/stocks/ups/earnings-date">United Parcel Service (NYSE: UPS)</a></strong>, and&nbsp;<strong><a href="https://stocksearning.com/stocks/KO/earnings-date">The Coca-Cola Company (NYSE: KO)</a></strong>.</p>



<p class="wp-block-paragraph">SCHD is particularly appealing for investors seeking a blend of income, quality, and long-term growth potential.</p>



<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="600" height="312" data-source="article-image" src="https://cms.stocksearning.com/wp-content/uploads/2026/04/SCHD_2026-04-27_11-01-36-600x312.png" alt="Dividend ETFs - StockEarnings" class="wp-image-1802" srcset="https://cms.stocksearning.com/wp-content/uploads/2026/04/SCHD_2026-04-27_11-01-36-600x312.png 600w, https://cms.stocksearning.com/wp-content/uploads/2026/04/SCHD_2026-04-27_11-01-36-300x156.png 300w, https://cms.stocksearning.com/wp-content/uploads/2026/04/SCHD_2026-04-27_11-01-36-768x400.png 768w, https://cms.stocksearning.com/wp-content/uploads/2026/04/SCHD_2026-04-27_11-01-36.png 1160w" sizes="auto, (max-width: 600px) 100vw, 600px" /></figure>



<h2 class="wp-block-heading" id="dividend-et-fs-offer-stability-in-any-market">Dividend ETFs Offer Stability in Any Market</h2>



<p class="wp-block-paragraph">In uncertain markets, stability and income become even more important. Dividend-focused ETFs—especially those emphasizing companies with long histories of growing payouts—can help anchor your portfolio.</p>



<p class="wp-block-paragraph">These funds don’t just provide income—they offer exposure to businesses that have proven their ability to navigate inflation, recessions, and shifting interest rate environments. That kind of consistency can reduce volatility while still allowing for long-term capital appreciation.</p>



<p class="wp-block-paragraph">While no ETF is exclusively dedicated to Dividend Kings, funds like NOBL, SCHV, and SCHD give investors access to many of the same high-quality characteristics: strong balance sheets, disciplined management, and shareholder-friendly capital allocation.</p>



<p class="wp-block-paragraph">For investors looking to balance risk and reward, these ETFs can serve as a core portfolio holding—delivering both reliability and growth potential over time.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://cms.stocksearning.com/2026/04/protect-portfolio-with-dividend-etfs/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>One of the Best Dividend-Paying ETFs to Own Now</title>
		<link>https://cms.stocksearning.com/2026/02/dividend-paying-etfs-to-own-now/</link>
					<comments>https://cms.stocksearning.com/2026/02/dividend-paying-etfs-to-own-now/#respond</comments>
		
		<dc:creator><![CDATA[Ian Cooper]]></dc:creator>
		<pubDate>Thu, 26 Feb 2026 12:00:00 +0000</pubDate>
				<category><![CDATA[Evergreen]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[COP]]></category>
		<category><![CDATA[CSCO]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[LMT]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[SCHB]]></category>
		<category><![CDATA[VZ]]></category>
		<guid isPermaLink="false">https://cms.stocksearning.com/?p=1239</guid>

					<description><![CDATA[Retirement should be about freedom and confidence, not anxiety. One of the most effective ways to create both is to own dividend-paying ETFs]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">Retirement should be about freedom and confidence, not anxiety. One of the most effective ways to create both is to own dividend-paying ETFs that deliver consistent cash flow, broad diversification, and professional management. These income-focused funds have surged in popularity among retirees and near-retirees precisely because they don&#8217;t require you to constantly sell shares to fund your lifestyle. Instead, dividend-paying ETFs turn your portfolio into a dependable income engine, and one that keeps working for you whether markets are calm or choppy.</p>



<div class="wp-block-rank-math-toc-block" id="rank-math-toc"><h2>Table of Contents</h2><nav><ul><li><a href="#collect-3-38-every-quarter">Collect 3.38% Every Quarter</a></li><li><a href="#high-standards-built-in-stability">High Standards, Built-In Stability</a></li><li><a href="#the-schd-etf-will-rebalance-in-march">The SCHD ETF Will Rebalance in March</a></li><li><a href="#a-smarter-alternative-to-your-savings-account">A Smarter Alternative to Your Savings Account</a></li></ul></nav></div>



<p class="wp-block-paragraph">But let&#8217;s take a step back and ask why this is important. </p>



<p class="wp-block-paragraph">After spending years building up your nest egg, you want to step into the retirement you deserve — whether that means relocating to a dream destination, traveling more, spending more time with family, or simply enjoying the comfort of your finances.</p>



<p class="wp-block-paragraph">What you&nbsp;<em>don’t</em>&nbsp;want is constant stress about market swings, inflation quietly eroding your purchasing power, or the fear of outliving your savings.&nbsp;&nbsp;You also don’t want to live on the scant 0.6% from your average savings account.</p>



<h2 class="wp-block-heading" id="collect-3-38-every-quarter">Collect 3.38% Every Quarter</h2>



<p class="wp-block-paragraph">One way to do that is by investing in a safe, high-yielding exchange traded fund (ETF), like the <strong>Schwab U.S. Dividend Equity ETF (NYSEARCA: SCHD)</strong>. With an ultra-low expense ratio of 0.06%, the SCHD ETF tracks the total return of the Dow Jones U.S. Dividend 100 Index. The fund currently holds 101 dividend-paying stocks, including blue-chip names such as <strong><a href="https://stocksearning.com/stocks/BMY/earnings-date">Bristol Myers Squibb (NYSE: BMY)</a></strong>, <strong><a href="https://stocksearning.com/stocks/MRK/earnings-date">Merck &amp; Co. (NYSE: MRK)</a></strong>, <strong><a href="https://stocksearning.com/stocks/COP/earnings-date">ConocoPhillips (NYSE: COP)</a></strong>, <strong><a href="https://stocksearning.com/stocks/LMT/earnings-date">Lockheed Martin Corp. (NYSE: LMT)</a></strong>, <strong><a href="https://stocksearning.com/stocks/CVX/earnings-date">Chevron (NYSE: CVX)</a></strong>, <strong><a href="https://stocksearning.com/stocks/VZ/earnings-date">Verizon Communications Inc. (NYSE: VZ)</a></strong>, and <strong><a href="https://stocksearning.com/stocks/CSCO/earnings-date">Cisco Systems (NASDAQ: CSCO)</a></strong>. </p>



<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="600" height="379" data-source="article-image" src="https://cms.stocksearning.com/wp-content/uploads/2026/02/SCHB-Fact-Sheet-1-600x379.png" alt="dividend-paying ETFs - StockEarnings" class="wp-image-1247" srcset="https://cms.stocksearning.com/wp-content/uploads/2026/02/SCHB-Fact-Sheet-1-600x379.png 600w, https://cms.stocksearning.com/wp-content/uploads/2026/02/SCHB-Fact-Sheet-1-300x189.png 300w, https://cms.stocksearning.com/wp-content/uploads/2026/02/SCHB-Fact-Sheet-1-768x485.png 768w, https://cms.stocksearning.com/wp-content/uploads/2026/02/SCHB-Fact-Sheet-1.png 1017w" sizes="auto, (max-width: 600px) 100vw, 600px" /></figure>



<p class="wp-block-paragraph">SCHD pays a quarterly dividend, making it a reliable source of regular income. It last paid out just over 27 cents per share on December 15. Before that, it distributed just over 26 cents per share on September 29 and just over 26 cents per share again on June 30. That kind of consistency is exactly what retirees need when planning monthly expenses.</p>



<p class="wp-block-paragraph">The ETF is also up about 15%&nbsp;since the start of the year after a lackluster 2025. This is a reminder that dividend-paying ETFs can offer growth potential alongside income.</p>



<h2 class="wp-block-heading" id="high-standards-built-in-stability">High Standards, Built-In Stability</h2>



<p class="wp-block-paragraph">What really sets SCHD apart from other dividend-paying ETFs is its<a href="https://www.schwabassetmanagement.com/resource/schd-fact-sheet" target="_blank" rel="noopener"> strict eligibility criteria</a>. To even be considered for inclusion, a company must have at least 10 consecutive years of dividend payouts, a market cap of no less than $500 million, and an average three-month daily trading volume of at least $2 million. In short, the ETF doesn&#8217;t accept any slouches. SCHD also favors companies carrying little to no debt, adding an extra layer of stability that matters when volatility picks up.</p>



<p class="wp-block-paragraph">This disciplined, rules-based approach is one reason SCHD has earned a strong reputation among investors who prioritize quality over yield-chasing. Many dividend-paying ETFs simply sweep up the highest yields available without regard for financial health — SCHD takes the opposite approach, screening for durability first.</p>



<h2 class="wp-block-heading" id="the-schd-etf-will-rebalance-in-march">The SCHD ETF Will Rebalance in March</h2>



<p class="wp-block-paragraph">In just weeks, the SCHD ETF will also undergo its annual rebalancing. This time around, it’s again expected to rotate out of stocks with compressed yields and into stocks with higher yields, which should include stocks in the financial and healthcare sectors.</p>



<p class="wp-block-paragraph">For investors keeping an eye on dividend-paying ETFs heading into the spring, this rebalancing could create a timely entry point. It offers a strong alternative. Owning a high-quality dividend ETF like SCHD can be a powerful step toward turning your hard-earned nest egg into lasting financial security.</p>



<h2 class="wp-block-heading" id="a-smarter-alternative-to-your-savings-account">A Smarter Alternative to Your Savings Account</h2>



<p class="wp-block-paragraph">The SCHD ETF has proven to be a reliable choice for those seeking income, stability, and long-term growth. And it provides all of that in a single, low-cost fund. For investors who want to replace the unreliable interest of a savings account with a consistent quarterly paycheck, without taking on excessive risk, SCHD offers a compelling alternative.</p>



<p class="wp-block-paragraph">Owning a high-quality dividend-paying ETF like SCHD can be a powerful step toward turning your hard-earned nest egg into lasting financial security — and the kind of retirement you&#8217;ve actually been working toward.</p>



<p class="wp-block-paragraph"></p>



<p class="wp-block-paragraph"></p>
]]></content:encoded>
					
					<wfw:commentRss>https://cms.stocksearning.com/2026/02/dividend-paying-etfs-to-own-now/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>The Dogs of the Dow for New Year 2026</title>
		<link>https://cms.stocksearning.com/2025/12/the-dogs-of-the-dow-for-2026/</link>
					<comments>https://cms.stocksearning.com/2025/12/the-dogs-of-the-dow-for-2026/#respond</comments>
		
		<dc:creator><![CDATA[Ian Cooper]]></dc:creator>
		<pubDate>Mon, 29 Dec 2025 20:00:00 +0000</pubDate>
				<category><![CDATA[Evergreen]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[CSCO]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[HD]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[KO]]></category>
		<category><![CDATA[MCD]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[NKE]]></category>
		<category><![CDATA[PG]]></category>
		<category><![CDATA[UNH]]></category>
		<category><![CDATA[VZ]]></category>
		<guid isPermaLink="false">https://cms.stocksearning.com/?p=711</guid>

					<description><![CDATA[Every year, one of the best strategies is the Dogs of the Dow. You simply buy a basket of underperformers on the Dow Jones Industrial Average (DJIA) that pay dividends, and sell them by the end of the year. The Strategy Behind the Dogs of the Dow The Dogs of the Dow strategy is made [&#8230;]]]></description>
										<content:encoded><![CDATA[
<p class="wp-block-paragraph">Every year, one of the best strategies is the Dogs of the Dow. You simply buy a basket of underperformers on the Dow Jones Industrial Average (DJIA) that pay dividends, and sell them by the end of the year.</p>



<div class="wp-block-rank-math-toc-block" id="rank-math-toc"><h2>Table of Contents</h2><nav><ul><li><a href="#the-strategy-behind-the-dogs-of-the-dow">The Strategy Behind the Dogs of the Dow</a></li><li><a href="#dogs-of-the-dow-2025-and-2026">Dogs of the Dow: 2025 and 2026</a></li><li><a href="#a-strategy-with-a-proven-track-record">A Strategy With a Proven Track Record</a></li><li><a href="#should-you-buy-the-dogs-of-the-dow-in-2026">Should You Buy the Dogs of the Dow in 2026?</a></li></ul></nav></div>



<h2 class="wp-block-heading" id="the-strategy-behind-the-dogs-of-the-dow">The Strategy Behind the Dogs of the Dow</h2>



<p class="wp-block-paragraph">The Dogs of the Dow strategy is made up of two distinct parts. The first is to invest, and the second is to rebalance. </p>



<p class="wp-block-paragraph">Part one: Invest equal amounts into the 10 highest-dividend-yielding stocks from the Dow Jones Industrial Average. Because the Dow Jones Industrial Average is widely regarded as a benchmark of the broader U.S. stock market, its component stocks represent the entire U.S. market. Furthermore, these are blue-chip stocks that are strong enough to withstand the test of time.</p>



<p class="wp-block-paragraph">Part Two: Rebalance the portfolio every year into equal amounts of the 10 highest-yielding stocks in the Dow. The rationale for doing this every year goes back to research that indicates that, over the long term, the strategy generates higher returns then buying shares of an index fund tied to the DJIA, or even the S&amp;P 500. </p>



<p class="wp-block-paragraph">It&#8217;s a deceptively easy strategy, but it requires discipline. If this strategy appeals to you, here&#8217;s a cheat sheet to help you execute this strategy in 2026.</p>



<h2 class="wp-block-heading" id="dogs-of-the-dow-2025-and-2026">Dogs of the Dow: 2025 and 2026</h2>



<p class="wp-block-paragraph">For 2025, here’s how the Dogs of the Dow are doing with just days to go.</p>



<ul class="wp-block-list">
<li><strong>Verizon (NYSE: VZ)</strong>, which yields 6.85%, started the year at around $38. It’s now up to $40.</li>



<li><strong><a href="https://stocksearning.com/stocks/CVX/earnings-date">Chevron (NYSE: CVX)</a></strong>, which yields 4.54%, ran from about $142 to $150.50.</li>



<li><strong><a href="https://stocksearning.com/stocks/JNJ/earnings-date">Johnson &amp; Johnson (NYSE: JNJ)</a></strong>, which yields 2.5%, ran from $142 to $207.78.</li>



<li><strong><a href="https://stocksearning.com/stocks/AMGN/earnings-date">Amgen (NASDAQ: AMGN)</a></strong>, which yields 3.02%, ran from about $258 to $334.</li>



<li><strong><a href="https://stocksearning.com/stocks/MRK/earnings-date">Merck (NYSE: MRK)</a></strong>, which yields 3.19%, traded between approximately $98 and $106.45.</li>



<li><strong><a href="https://stocksearning.com/stocks/KO/earnings-date">Coca-Cola (NYSE: KO)</a></strong>, which yields 2.91%, jumped from $61 to $70.11 so far.</li>



<li><strong><a href="https://www.marketbeat.com/stocks/NYSE/IBM/" target="_blank" rel="noopener">IBM (NYSE: IBM)</a></strong>, which yields 2.21%, ran from about $215 to a $304.56.</li>



<li><strong><a href="https://stocksearning.com/stocks/CSCO/earnings-date">Cisco (NASDAQ: CSCO)</a></strong>, which yields 2.1%, ran from about $58 to $78.</li>



<li><strong><a href="https://stocksearning.com/stocks/MCD/earnings-date">McDonald’s (NYSE: MCD)</a></strong>, which yields 2.37%, ran from about $293 to $313.</li>



<li><strong><a href="https://stocksearning.com/stocks/PG/earnings-date">Procter &amp; Gamble (NYSE: PG)</a></strong>, which yields 2.93%, fell from about $264 to $144.50.</li>
</ul>



<p class="wp-block-paragraph">That’s not bad at all.</p>



<p class="wp-block-paragraph">Plus, once you factor in the yields for each, the Dogs of the Dow outperformed the Dow Jones.</p>



<p class="wp-block-paragraph">As for 2026, while the official list isn’t out just yet, here’s what’s likely to make the list.</p>



<ul class="wp-block-list">
<li><strong>Verizon (VZ)</strong>, which yields 6.84%</li>



<li><strong>Chevron (CVX)</strong>, which yields 4.56%</li>



<li><strong>Merck (MRK)</strong>, which yields 3.2%</li>



<li><strong>Procter &amp; Gamble (PG</strong>), which yields 2.92%</li>



<li><strong>Amgen (AMGN)</strong>, which yields 3.04%</li>



<li><strong>Coca-Cola (KO)</strong>, which yields 2.92%</li>



<li><strong><a href="https://stocksearning.com/stocks/NKE/earnings-date">Nike (NYSE: NKE)</a></strong>, which yields 2.72%</li>



<li><strong><a href="https://www.marketbeat.com/stocks/NYSE/UNH/" target="_blank" rel="noopener">UnitedHealth (NYSE: UNH)</a></strong>, which yields 2.68%</li>



<li><strong><a href="https://stocksearning.com/stocks/HD/earnings-date">Home Depot (NYSE: HD)</a></strong>, which yields 2.64%</li>



<li><strong>Johnson &amp; Johnson (JNJ)</strong>, which yields 2.51%</li>
</ul>



<h2 class="wp-block-heading" id="a-strategy-with-a-proven-track-record">A Strategy With a Proven Track Record</h2>



<p class="wp-block-paragraph">Historically, the Dogs of the Dow do very well for income-oriented investors. </p>



<ul class="wp-block-list">
<li>The 2024 Dogs of the Dow underperformed the major indices in 2024. However, with dividends, investors still did well for the year.</li>



<li>The 2023 Dogs of the Dow returned an average of 10.1%, which came in below the 14.4% return on the Dow Jones’ Industrials. Still, with the appreciation in most of the 2023 Dogs coupled with dividends, investors still did well overall.</li>



<li>The 2022 Dogs of the Dow beat the major indices, even in a rough year.</li>
</ul>



<p class="wp-block-paragraph">In fact, while the Dogs of the Dow stocks fell 1.6% on the year, once you add in the dividend payouts, the Dogs returned 2% on the year.&nbsp;And while 2% may not sound like a big win, consider that, in 2022, one of the worst years on record since 2008, the NASDAQ lost 33%.&nbsp; The S&amp;P 500 lost 19%.&nbsp; The Dow Jones lost about 9%.</p>



<ul class="wp-block-list">
<li>In 2021, the Dogs of the Dow returned about 16.3%. </li>



<li>In 2019, the Dogs were up 20%.&nbsp; </li>



<li>In 2018, they were up about 1%, but still beat the Dow, which fell close to 6%.&nbsp;</li>



<li>In 2017, the dogs were up 19%.&nbsp; In 2016, they were up 16%.</li>
</ul>



<p class="wp-block-paragraph">While 2020 wasn’t a great year for the Dogs, it wasn&#8217;t great for a lot of stocks for obvious reasons. However, most other years, the Dogs of the Dow have performed very well.&nbsp; </p>



<h2 class="wp-block-heading" id="should-you-buy-the-dogs-of-the-dow-in-2026">Should You Buy the Dogs of the Dow in 2026?</h2>



<p class="wp-block-paragraph">The Dogs of the Dow remains one of the simplest income strategies available to retail investors, and its track record speaks for itself. While the strategy doesn’t outperform every year, the long-term results show consistent dividend income and competitive total returns, especially during volatile market cycles. With yields still attractive and several blue-chip names likely to appear on the 2026 list, the setup for the coming year looks compelling. As always, discipline and annual rebalancing are key. For patient investors who value simplicity and dependable dividends, the Dogs of the Dow remain worth serious consideration.</p>



<p class="wp-block-paragraph"></p>
]]></content:encoded>
					
					<wfw:commentRss>https://cms.stocksearning.com/2025/12/the-dogs-of-the-dow-for-2026/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>
